Changes of RAS Pathway Phosphorylation in Lymphoblastoid Cell Lines from Noonan Syndrome Patients Carrying Hypomorphic Variants in Two NS Genes
暂无分享,去创建一个
[1] M. Zenker,et al. Noonan syndrome: improving recognition and diagnosis , 2022, Archives of Disease in Childhood.
[2] R. Elder,et al. Noonan syndrome and pregnancy outcomes , 2022, Cardiology in the Young.
[3] Jiang Zheng,et al. Shenxiong glucose injection inhibits H2O2-induced H9c2 cell apoptosis by activating the ERK signaling pathway. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] F. He,et al. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. , 2021, Molecular cell.
[5] J. Lacal,et al. Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins , 2021, Orphanet Journal of Rare Diseases.
[6] J. F. Longo,et al. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells , 2020, Cell Communication and Signaling.
[7] C. Battaglia,et al. Digenic inheritance of subclinical variants in Noonan Syndrome patients: an alternative pathogenic model? , 2020, European Journal of Human Genetics.
[8] B. Gelb,et al. Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment , 2020, American journal of medical genetics. Part C, Seminars in medical genetics.
[9] S. Baek,et al. Neurodevelopmental Aspects of RASopathies , 2019, Molecules and cells.
[10] H. Ohashi,et al. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1–PPP1CB complexes , 2018, Human Genetics.
[11] D. Lacombe,et al. RAS signalling in energy metabolism and rare human diseases. , 2018, Biochimica et biophysica acta. Bioenergetics.
[12] E. I. Pierpont,et al. Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1 , 2018, Journal of Neurodevelopmental Disorders.
[13] E. I. Pierpont,et al. Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1 , 2018, Journal of Neurodevelopmental Disorders.
[14] J. Allanson,et al. Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies , 2018, Scientific Reports.
[15] J. Rosenfeld,et al. Autosomal Recessive Noonan Syndrome Associated with Biallelic LZTR1Variants , 2017, Genetics in Medicine.
[16] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[17] P. Sachdev,et al. Application of Targeted Mass Spectrometry for the Quantification of Sirtuins in the Central Nervous System , 2016, Scientific Reports.
[18] L. Castagnoli,et al. Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase. , 2016, New biotechnology.
[19] J. Allanson. Objective studies of the face of Noonan, Cardio‐facio‐cutaneous, and Costello syndromes: A comparison of three disorders of the Ras/MAPK signaling pathway , 2016, American journal of medical genetics. Part A.
[20] Yoichi Matsubara,et al. Recent advances in RASopathies , 2015, Journal of Human Genetics.
[21] J. F. Longo,et al. Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells , 2015, Journal of neuropathology and experimental neurology.
[22] A. Heck,et al. Phosphoproteomics-Mediated Identification of Fer Kinase as a Target of Mutant Shp2 in Noonan and LEOPARD Syndrome , 2014, PloS one.
[23] A. Heck,et al. PZR Coordinates Shp2 Noonan and LEOPARD Syndrome Signaling in Zebrafish and Mice , 2014, Molecular and Cellular Biology.
[24] Jian Wang,et al. Rare copy number variations containing genes involved in RASopathies: deletion of SHOC2 and duplication of PTPN11 , 2014, Molecular Cytogenetics.
[25] Andreas Krämer,et al. Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..
[26] O. Gabrielli,et al. SOS1 Mutations in Noonan Syndrome: Molecular Spectrum, Structural Insights on Pathogenic Effects, and Genotype–Phenotype Correlations , 2011, Human mutation.
[27] J. Allanson,et al. Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines , 2010, Pediatrics.
[28] M. Cisternino,et al. Noonan syndrome associated with both a new Jnk‐activating familial SOS1 and a de novo RAF1 mutations , 2010, American journal of medical genetics. Part A.
[29] M. Mann,et al. Universal sample preparation method for proteome analysis , 2009, Nature Methods.
[30] I. van der Burgt,et al. Noonan Syndrome , 2019, Encyclopedia of Endocrine Diseases.
[31] J. Wiśniewski. Filter-Aided Sample Preparation for Proteome Analysis. , 2018, Methods in molecular biology.
[32] C. Eyers. Universal sample preparation method for proteome analysis , 2009 .